<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005873</url>
  </required_header>
  <id_info>
    <org_study_id>TLC599A2003</org_study_id>
    <nct_id>NCT03005873</nct_id>
  </id_info>
  <brief_title>A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee</brief_title>
  <official_title>A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Liposome Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Liposome Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study
      to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol No: TLC599A2003 Name of Finished Product: TLC599

      Title of Study:

      A Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study for Single
      dose Administration of TLC599 in Patients with Osteoarthritis (OA) of Knee.

      Study duration:

      The trial will last around 27 weeks including a 21-day screening period and a 24-week
      follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC questionnaire pain sub-scale</measure>
    <time_frame>at Week 12 after dosing</time_frame>
    <description>The primary endpoint is to evaluate the change from baseline by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC questionnaire</measure>
    <time_frame>at Weeks 1, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in pain / function subscales of WOMAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score (VAS)</measure>
    <time_frame>at Weeks 1, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in the patient rated visual analogue scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5 Dimension questionnaire</measure>
    <time_frame>at Weeks 1, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Change from baseline to Weeks 1, 4, 8, 12, 16, 20, and 24 in EuroQol-5 Dimension questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage of acetaminophen</measure>
    <time_frame>at Weeks 1, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Total consumption of acetaminophen at Weeks 1, 4, 8, 12, 16, 20, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>up to 24 weeks after dosing</time_frame>
    <description>To evaluate the safety and tolerability of TLC599 by incidence of Treatment-Emergent Adverse Events reported by Investigators</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Low-dose test drug group (LD group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg DSP with 100 µmol PL (1.0 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose test drug group (HD group):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 mg DSP with 150 µmol PL (1.5 mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.5 mL normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TLC599</intervention_name>
    <description>Single dose via intra-articular injection</description>
    <arm_group_label>Low-dose test drug group (LD group)</arm_group_label>
    <arm_group_label>High-dose test drug group (HD group):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Single dose via intra-articular injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Male or female patients, at least 50 years of age.

          2. Documented diagnosis of OA of the knee for at least 6 months

          3. The study knee has OA with Grade 2 to 3 severity based on the Kellgren Lawrence grades

          4. Patients with patient related visual analogue scale (VAS) score of 5.0 to 9.0 at
             baseline.

          5. Willing and able to comply with study procedures and provide written informed consent.

        Main Exclusion Criteria:

          1. Patients who received systemic corticosteroids within the last 30 days prior to
             dosing.

          2. Patients who use prohibited medications within 7 days prior to study drug
             administration or any pain control medication including acetaminophen within 48 hours
             prior to study drug administration.

          3. Patients who use prohibited medications other than acetaminophen and oral NSAIDs from
             screening visit to 7 days prior to study drug administration.

          4. Documented history and confirmed autoimmune disease

          5. History of post-traumatic knee arthritis, or evidence of intra articular bleeding of
             the study knee

          6. History of infective arthritis

          7. Unstable study knee joint

          8. Use of IA corticosteroid, hyaluronic acid, or other IA injection in the study knee
             within 3 months prior to the screening visit.

          9. A history of treated malignancy which is disease free for ≤ 5 years prior to the
             screening visit

         10. Uncontrolled and unstable concurrent medical or psychiatric illness, that will
             jeopardize the safety of the patient

         11. Use of any chemotherapeutic or systemic immunosuppressant agents for inflammatory
             diseases within 6 months prior to the screening visit.

         12. Current use of anticoagulants, including warfarin, heparin, low molecular weight
             heparin, or dabigatran.

         13. Abnormalities of laboratory parameters as described below will qualify for exclusion:

               -  hemoglobin &lt; 8 g/dL;

               -  total white blood cell count &lt; 4000/ µL;

               -  serum bilirubin/ alanine aminotransferase/ aspartate aminotransferase &gt; 2 times
                  upper limit of normal (ULN) for the laboratory reference ranges;

               -  serum creatinine &gt; 2 times ULN for the laboratory reference range;

               -  serum uric acid &gt; ULN for the laboratory reference range;

               -  prothrombin time/International Normalized Ratio &gt; ULN for the laboratory
                  reference range.

         14. Contraindication to undergoing magnetic resonance imaging (MRI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Genesis Research Services Pty Limited</name>
      <address>
        <city>Broadmeadow</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pendlebury Clinic Private Hospital</name>
      <address>
        <city>Cardiff</city>
        <zip>2285</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Footscray Hospital- Western Health</name>
      <address>
        <city>Footscray</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands,</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Show Chwan Memorial Hospital</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical Universtiy Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis of the knee</keyword>
  <keyword>TLC599</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>DSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

